Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
“Our pharmacy team moves mountains to ensure patients don’t lose access to their medications — and don’t spend hours on the phone navigating this problem alone.” AndHealth is actively enrolling adults ...